GCP
CHRS icon

GSA Capital Partners’s Coherus Oncology CHRS Stock Holding History

GSA Capital Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$531K Buy
379,355
+59,700
+19% +$97.5K 0.03% 962
2026
Q1 		$540K Sell
319,655
-157,826
-33% -$280K 0.03% 866
2025
Q4 		$678K Buy
+477,481
New +$696K 0.06% 616
2025
Q2 		– Sell
-10,153
Closed -$8K – 1779
2025
Q1 		$8K Sell
10,153
-112,869
-92% -$130K ﹤0.01% 1594
2024
Q4 		$170K Buy
+123,022
New +$138K 0.01% 1452
2024
Q1 		– Sell
-23,950
Closed -$80K – 1649
2023
Q4 		$80K Sell
23,950
-72,703
-75% -$195K 0.01% 1406
2023
Q3 		$361K Sell
96,653
-24,726
-20% -$114K 0.03% 977
2023
Q2 		$518K Buy
121,379
+55,702
+85% +$329K 0.05% 709
2023
Q1 		$449K Sell
65,677
-11,362
-15% -$88.2K 0.04% 783
2022
Q4 		$610K Buy
+77,039
New +$593K 0.08% 477
2022
Q1 		– Sell
-17,781
Closed -$284K – 1459
2021
Q4 		$284K Buy
+17,781
New +$311K 0.04% 970
2021
Q3 		– Sell
-12,453
Closed -$172K – 1470
2021
Q2 		$172K Buy
+12,453
New +$176K 0.02% 1206
2020
Q1 		– Sell
-42,933
Closed -$773K – 1111
2019
Q4 		$773K Buy
42,933
+29,122
+211% +$537K 0.09% 355
2019
Q3 		$280K Buy
+13,811
New +$276K 0.04% 952

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

GSA Capital Partners's CHRS Position: Q2 2026 in Review

GSA Capital Partners increased its Coherus Oncology (CHRS) stake by 19% in Q2 2026, buying an estimated $97.5K and bringing the position to 379,355 shares worth $531K. The position accounts for 0.03% of the portfolio, ranked #962.

GSA Capital Partners first reported a position in CHRS in Q3 2019 and has held it in 14 quarters since. The position peaked at $773K in Q4 2019. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • GSA Capital Partners held 379,355 shares of Coherus Oncology worth $531K as of Q2 2026.
  • GSA Capital Partners bought 59,700 Coherus Oncology shares in Q2 2026, an estimated $97.5K.
  • Coherus Oncology made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #962 holding.
  • GSA Capital Partners first reported a position in Coherus Oncology in Q3 2019 and has held it in 14 quarters since.
  • GSA Capital Partners's Coherus Oncology position peaked at $773K in Q4 2019.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.